This brand name is authorized in Austria, Cyprus, Estonia, Spain, Finland, France, Ireland, Israel, Lithuania, Netherlands, Poland, United Kingdom
The drug EVIPLERA contains a combination of these active pharmaceutical ingredients (APIs):
1
Emtricitabine
UNII G70B4ETF4S - EMTRICITABINE
|
Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to HIV-1, HIV-2 and HBV. Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competitively inhibits HIV-1 reverse transcriptase, resulting in DNA chain termination. Emtricitabine is a weak inhibitor of mammalian DNA polymerase α, β and ε and mitochondrial DNA polymerase γ. |
2
Rilpivirine
UNII 212WAX8KDD - RILPIVIRINE HYDROCHLORIDE
|
Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ. |
3
Tenofovir disoproxil
UNII OTT9J7900I - TENOFOVIR DISOPROXIL FUMARATE
|
Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
EVIPLERA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
J05AR08 | Emtricitabine, tenofovir disoproxil and rilpivirine | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: EE | Ravimiamet | Identifier(s): 1550731, 1550742 |
Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 11737001 |
Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 441619 |
Country: FR | Base de données publique des médicaments | Identifier(s): 63578537 |
Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 205590 |
Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 7167 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1063757, 1063758 |
Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 146552 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100087050 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.